Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab and ABL Bio Report Preliminary Efficacy of PD-L1/4-1BB Bispecific

publication date: Oct 11, 2023

Shanghai I-Mab reported positive early results from a US/Korea Phase I trial of a novel PD-L1 x 4-1BB bispecific antibody as a second-line therapy for solid tumors that were resistant to PD-(L)1 therapies. The bispecific, developed by ABL Bio of South Korea, is a combination of I-Mab’s TJ-L14B and ABL’s ABL503. Its PD-L1 arm is a tumor-dependent T-cell activator, while the 4-1BB arm activates T cells after binding the PD-(L)1 target. At a low dose, TJ-L14B/ABL produced one complete response and three partial response in 14 patients. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital